Nurix Therapeutics, Inc.
NRIX Healthcare Biotechnology
Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024. In the quarter to August 2026, revenue grew 8,426.3%, EPS grew 578.5% and free cash flow grew 1,122.1%, each against the same quarter a year earlier.
Follow NRIX
Nurix Therapeutics, Inc. (NRIX) Altman Z-score
Nurix Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is 3.77, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 3.77 | (0.91) |
| FY2024 | 4.68 | 6.04 |
| FY2023 | −1.36 | (2.56) |
| FY2022 | 1.20 | (3.53) |
| FY2021 | 4.73 | 1.05 |
| FY2020 | 3.68 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.76 | — | 0.91 | |
| Retained earnings / total assets | (1.46) | — | −2.04 | |
| EBIT / total assets | (0.42) | — | −1.37 | |
| Market value of equity / total liabilities | 10.26 | — | 6.15 | |
| Sales / total assets | 0.12 | — | 0.12 | |
| Altman Z-score | Safe zone | 3.77 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Grey zone | 1.20 | ||
Z and Z″ put Nurix Therapeutics, Inc. in different zones: safe zone by Z, grey zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| DNLI Denali Therapeutics Inc. compare | 13.8× |
| BEAM Beam Therapeutics Inc. compare | 5.4× |
| NRIX Nurix Therapeutics, Inc. | 3.8× |
| RCUS Arcus Biosciences, Inc. compare | 1.1× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −0.2× |
| PGEN Precigen, Inc. compare | −16.9× |
| CELC Celcuity, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
| ELVN Enliven Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets